Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 ...
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and ...